Contrast-induced acute kidney injury following PCI

European Journal of Clinical Investigation

Volumn 43, Issue 5, 2013, Pages 483-490

  Tehrani, Shana ^a   Laing, Chris ^b,c   Yellon, Derek M ^a   Hausenloy, Derek J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Biomarkers of acute kidney injury; Contrast induced acute kidney injury; Percutaneous coronary intervention

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SODIUM CHLORIDE;

ABDOMINAL AORTA ANEURYSM; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; CONGESTIVE HEART FAILURE; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS GRAFT; CYTOTOXICITY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HOSPITAL PATIENT; HUMAN; HYDRATION; HYPOVOLEMIA; INSULIN RELEASE; ISCHEMIC PRECONDITIONING; LIVER FAILURE; NEPHROTOXICITY; OSMOLALITY; PANCREAS ISLET BETA CELL; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; SUGAR TRANSPORT;

ACUTE KIDNEY INJURY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; HOSPITAL MORTALITY; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTORS;

EID: 84876459504     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12061     Document Type: Review

References (94)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, de SG et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:e46-215.
2. Blackman DJ, Pinto R, Ross JR, Seidelin PH, Ing D, Jackevicius C et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J 2006;151:146-52.
3. Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, Satler LF et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:338-43.
4. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006;98:5K-13K.
5. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-64.
6. Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007;18:1292-8.
7. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-6.
8. Scheller B. How to protect from contrast media-induced nephropathy? Clin Res Cardiol 2007;96:125-9.
9. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
10. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001;52:409-16.
11. Stacul F, Van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011;21:2527-41.
12. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143-9.
13. Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989;320:149-53.
14. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005;172:1461-71.
15. Reinecke H, Trey T, Matzkies F, Fobker M, Breithardt G, Schaefer RM. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int 2003;63:696-701.
16. Thomsen HS, Morcos SK. Management of acute adverse reactions to contrast media. Eur Radiol 2004;14:476-81.
17. Weisbord SD, Palevsky PM. Contrast-induced acute kidney injury: short- and long-term implications. Semin Nephrol 2011;31:300-9.
18. From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS. Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc 2008;83:1095-100.
19. Shema L, Ore L, Geron R, Kristal B. Contrast-induced nephropathy among Israeli hospitalized patients: incidence, risk factors, length of stay and mortality. Isr Med Assoc J 2009;11:460-4.
20. Goldenberg I, Chonchol M, Guetta V. Reversible acute kidney injury following contrast exposure and the risk of long-term mortality. Am J Nephrol 2009;29:136-44.
21. Morcos SK. Prevention of contrast media nephrotoxicity-the story so far. Clin Radiol 2004;59:381-9.
22. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003;4(Suppl. 5):S3-9.
23. Morcos SK. Contrast nephrotoxicity and iso-osmolar contrast agents: implications of nephric. Clin Radiol 2004;59:297.
24. Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl 2006;100:S51-3.
25. Caixeta A, Mehran R. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. Catheter Cardiovasc Interv 2010;75(Suppl. 1):S15-20.
26. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJr.Am J Roentgenol 2004;183:1673-89.
27. Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004;79:211-9.
28. Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005;235:843-9.
29. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 2008;49:646-57.
30. Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J 2012;33:2007-15.
31. McCullough P. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv 2006;67:335-43.
32. Almen T. Visipaque-a step forward. A historical review. Acta Radiol Suppl 1995;399:2-18.
33. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De NL. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995;6:1451-8.
34. Gupta R, Gurm HS, Bhatt DL, Chew DP, Ellis SG. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv 2005;64:442-8.
35. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98:14K-20K.
36. Calvin AD, Misra S, Pflueger A. Contrast-induced acute kidney injury and diabetic nephropathy. Nat Rev Nephrol 2010;6:679-88.
37. Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol 2008;21:74-85.
38. Deray G, Baumelou B, Martinez F, Brillet G, Jacobs C. Renal vasoconstriction after low and high osmolar contrast agents in ischemic and non ischemic canine kidney. Clin Nephrol 1991;36:93-6.
39. Talner LB, Davidson AJ. Renal hemodynamic effects of contrast media. Invest Radiol 1968;3:310-7.
40. Humes HD, Hunt DA, White MD. Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubule cells. Am J Physiol 1987;252:F246-55.
41. Arend LJ, Bakris GL, Burnett JC Jr, Megerian C, Spielman WS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987;110:406-11.
42. Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 1992;41:1408-15.
43. Baars T, Kleinbongard P, Bose D, Konorza T, Mohlenkamp S, Hippler J et al. Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential. Basic Res Cardiol 2012;107:303.
44. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:254-61.
45. Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med 2006;34:2060-8.
46. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005;289:F420-30.
47. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515-9.
48. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003;15:18-22.
49. Alamartine E, Phayphet M, Thibaudin D, Barral FG, Veyret C. Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations. Eur J Intern Med 2003;14:426-31.
50. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999;34:685-91.
51. Evenepoel P. Acute toxic renal failure. Best Pract Res Clin Anaesthesiol 2004;18:37-52.
52. Wickenbrock I, Perings C, Maagh P, Quack I, van BM, Prull MW et al. Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. Clin Res Cardiol 2009;98:765-72.
53. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De BD et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006;10:R73.
54. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
55. Kellum JA. KDIGO clinical practice guideline for acute kidney injury. In: 2, 1; doi:10.1038/kisup.2012.1 ed, 2012.
56. Schiffl H, Lang SM. Update on biomarkers of acute kidney injury: moving closer to clinical impact? Mol Diagn Ther 2012;16:199-207.
57. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012;50:1505-17.
58. Schinstock CA, Semret MH, Wagner SJ, Borland TM, Bryant SC, Kashani KB et al. Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. Nephrol Dial Transplant 2012; [Epub ahead of print].
59. Buelow MW, Dall A, Regner K, Weinberg C, Bartz PJ, Sowinski J et al. Urinary interleukin-18 and urinary neutrophil gelatinase-associated lipocalin predict acute kidney injury following pulmonary valve replacement prior to serum creatinine. Congenit Heart Dis 2012;7:441-7.
60. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:1012-24.
61. Heller F, Frischmann S, Grunbaum M, Zidek W, Westhoff TH. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol 2011;6:2347-55.
62. Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol 2008;51:89-90.
63. Erley CM. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant 1999;14:1064-6.
64. Hafiz AM, Jan MF, Mori N, Shaikh F, Wallach J, Bajwa T et al. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies. Catheter Cardiovasc Interv 2012;79:929-37.
65. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-36.
66. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998;32:64-71.
67. Atkins JL. Effect of sodium bicarbonate preloading on ischemic renal failure. Nephron 1986;44:70-4.
68. Adolph E, Holdt-Lehmann B, Chatterjee T, Paschka S, Prott A, Schneider H et al. Renal insufficiency following radiocontrast exposure trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis 2008;19:413-9.
69. Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 2008;52:599-604.
70. Tamura A, Goto Y, Miyamoto K, Naono S, Kawano Y, Kotoku M et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol 2009;104:921-5.
71. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008;300:1038-46.
72. Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med 2009;7:23.
73. Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 2009;53:617-27.
74. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim TH et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury. Circ J 2012;76:2255-65.
75. Hoste EA, De Waele JJ, Gevaert SA, Uchino S, Kellum JA. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant 2010;25:747-58.
76. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al SA et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004;148:422-9.
77. Tanaka A, Suzuki Y, Suzuki N, Hirai T, Yasuda N, Miki K et al. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction? Intern Med 2011;50:673-7.
78. Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 2004;25:212-8.
79. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263-72.
80. Munzel T, Keaney JF Jr. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001;104:1571-4.
81. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999;51:521-6.
82. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL. [The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography]. Anadolu Kardiyol Derg 2003;3:98-103.
83. Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006;104:c20-7.
84. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 2004;44:1763-71.
85. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von BC et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002;106:2180-3.
86. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005;118:843-9.
87. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112:171-8.
88. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155-63.
89. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007;50:409-18.
90. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-9.
91. Walsh SR, Boyle JR, Tang TY, Sadat U, Cooper DG, Lapsley M et al. Remote ischemic preconditioning for renal and cardiac protection during endovascular aneurysm repair: a randomized controlled trial. J Endovasc Ther 2009;16:680-9.
92. Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM et al. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 2007;116:I98-105.
93. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J et al. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 2010;105:657-64.
94. Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E et al. Ischemic preconditioning for prevention of contrast-medium-induced nephropathy: randomized pilot renpro-trial (renal protection trial). Circulation 2012;52:230.